Formycon

Formycon EBIT

The EBIT of Formycon (FYB.DE) as of Nov 6, 2026 is -29.37 M EUR. In the previous year, EBIT was -23.54 M EUR — a change of 24.74% (lower).

EBIT

-29.37 MEUR

YoY

24.74%

Last updated:

In 2025, Formycon's EBIT was -29.37 M EUR, a 24.74% increase from the -23.54 M EUR EBIT recorded in the previous year.

The Formycon EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2022
-17.73 M EUR
Jan 1, 2023
-369,000.00 EUR
Jan 1, 2024
-23.54 M EUR
Jan 1, 2025
-29.37 M EUR
Jan 1, 2026 (e)
2.09 M EUR
Jan 1, 2027 (e)
39.59 M EUR
Jan 1, 2028 (e)
42.56 M EUR
Jan 1, 2029 (e)
62.00 M EUR
The Formycon EBIT history
YEAREBITYoY
est62.00 MEUR+45.70%
est42.56 MEUR+7.48%
est39.59 MEUR+1,794.31%
est2.09 MEUR-107.12%
-29.37 MEUR+24.74%
-23.54 MEUR+6,280.22%
-369,000.00EUR-97.92%
-17.73 MEUR+26.24%
-14.04 MEUR+114.69%
-6.54 MEUR+187.69%
-2.27 MEUR-131.94%
7.12 MEUR-562.11%
-1.54 MEUR-61.90%
-4.04 MEUR-708.05%
665,012.00EUR-23.63%
870,794.00EUR-111.26%
-7.74 MEUR+236.95%
-2.30 MEUR+78.54%
-1.29 MEUR+26.14%
-1.02 MEUR+433.82%
-191,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Revenue

Formycon Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
42.50 M EUR
-17.73 M EUR
35.99 M EUR
Jan 1, 2023
77.70 M EUR
-369,000.00 EUR
75.80 M EUR
Jan 1, 2024
69.67 M EUR
-23.54 M EUR
-125.67 M EUR
Jan 1, 2025
44.48 M EUR
-29.37 M EUR
-64.70 M EUR
Jan 1, 2026 (e)
80.78 M EUR
2.09 M EUR
568,483.50 EUR
Jan 1, 2027 (e)
116.80 M EUR
39.59 M EUR
33.63 M EUR
Jan 1, 2028 (e)
100.50 M EUR
42.56 M EUR
36.47 M EUR
Jan 1, 2029 (e)
159.66 M EUR
62.00 M EUR
53.52 M EUR

Formycon Margins

Formycon stock margins

The Formycon margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Formycon. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Formycon.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
28.41 %
-41.72 %
84.69 %
Jan 1, 2023
30.00 %
-0.47 %
97.55 %
Jan 1, 2024
21.29 %
-33.79 %
-180.37 %
Jan 1, 2025
8.04 %
-66.03 %
-145.46 %
Jan 1, 2026 (e)
8.04 %
2.59 %
0.70 %
Jan 1, 2027 (e)
8.04 %
33.90 %
28.79 %
Jan 1, 2028 (e)
8.04 %
42.35 %
36.29 %
Jan 1, 2029 (e)
8.04 %
38.84 %
33.53 %

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Formycon's EBIT

Formycon's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Formycon's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Formycon's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Formycon’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Formycon stock

EBIT of Formycon is -29.37 M EUR in 2025.

EBIT of Formycon changed from -23.54 M EUR to -29.37 M EUR, representing a 24.74% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Formycon since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Formycon historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Formycon

All Key Metrics — Formycon